GSK (GSK.L) research
GSK plc is a focused biopharmaceutical company that develops specialty medicines, vaccines and general medicines, with research priorities spanning respiratory and immune-mediated disease, oncology, HIV and infectious diseases.
Investment Score
The deterministic Investment Score for GSK (score 69, mechanical rating: Buy, confidence 83) is driven primarily by strong valuation, growth and profitability signals in the available data, while Financial Health and Dividend Sustainability materially reduce the overall picture. Valuation (score 81), Growth (85) and Profitability (85) together contribute the bulk of the positive signal (each contributing ~18–19 points). By contrast Financial Health (score 46) and Dividend Sustainability (score 25) constrain upside, reflecting leverage, a sub-1 current ratio and unclear free-cash-flow/dividend coverage. Key data gaps (revenue recorded as 0, multiple ‘n/a’ ratios, and no analyst consensus) limit the granularity of the assessment and should be considered when interpreting the score. This is research and education only, not investment advice.
Score: 69
Dividend evidence
- Ex-dividend 13 August 2026 · £0.17 · estimated · Yahoo
Sources and limitations
Last updated 2 August 2026. Historical payments do not guarantee future distributions. Research and educational information only.